agenda

AGENDA
Translational Advances in Cancer Prevention Agent Development
Sponsored by the Division of Cancer Prevention, National Cancer Institute
and the Office of Disease Prevention
National Institutes of Health
Bethesda, MD 20892
DATE: August 27-29, 2020
Day 1 Morning Session (8:00 to 12:00)
7:00-8:00 AM

Registration (Please allow sufficient time to go through security)

8:00-8:30 AM

Welcome Remarks
Deborah Winn, Ph.D., Acting Director, Division of Cancer Prevention, NCI
Mark Miller, Ph.D. Program Director, Division of Cancer Prevention, NCI

8:30-9:30 AM

Translational Research Plenary Speaker
Raymond DuBois, M.D., Ph.D., Medical University of South Carolina
Inflammation and inflammatory mediators as targets for cancer
prevention/interception
Session I*
Advances in Small Molecule Agent Development
Co-Chairs: Margie Clapper, Ph.D. and Thomas Kensler, Ph.D.

9:30-10:00 AM

Speaker 1: Margie Clapper, Ph.D. Fox Chase Cancer Center
Estrogen metabolism: A target for intervention in non-small cell lung cancer

10:00-10:30 AM

Speaker 2: Thomas Kensler, Ph.D., Fred Hutchinson Cancer Research Center
Bringing broccoli sprouts (Sulforaphane) to clinical trials: dose matters

10:30-10:50 AM

Break

10:50-11:20 AM

Speaker 3: Zelton (Dave) Sharp, Ph.D., University of Texas at San Antonio
Cancer and aging prevention by mTOR inhibition

11:20-11:50 AM

Speaker 4: Karen Liby, Ph.D., Michigan State University
Targeting the immune system for the prevention of Kras-driven cancers

11:50-1:15 PM

Lunch

*Session talks will be 25 min with 5 min Q&A

Day 1 Afternoon Session (1:15 to 4:30)
Session II
Advances in Immunomodulatory Agent Development
Co-chairs: Jill Siegfried, Ph.D. and Robert H. Shoemaker, Ph.D.
1:15-1:45 PM

Speaker 1: Jill Siegfried, Ph.D., University of Minnesota
A STAT3 decoy for lung cancer prevention

1:45-2:15 PM

Speaker 2: Robert Glynn, Sc.D., Harvard Medical School
Mediation analysis to elucidate the role of inflammation reduction in cancer
prevention: exploratory findings from the CANTOS trial

2:15-2:45 PM

Speaker 3: Haval Shirwan, Ph.D., University of Missouri, Columbia
CD137 immune checkpoint pathway as an effective target for cancer
immunoprevention

2:45-3:00 PM

Break

3:00-3:30 PM

Speaker 4: Shadmehr Demehri, M.D., Ph.D., Massachusetts General Hospital
Epithelium-derived alarmins role in breast cancer immunoprevention

3:30-3:50 PM

NCI PREVENT Preclinical Drug Development Program
Mark Miller, Ph.D., Division of Cancer Prevention, NCI

Q&A Session until 4:30 PM

4:30-6:00 PM

Poster Session

Day 2 Morning Session (9:00 to12:00)
Session III
Alternative Dosing and Combination Strategies to Reduce Toxicity
Co-Chairs: Ming You, M.D., Ph.D. and Altaf Mohammed, Ph.D.
9:00-9:30 AM

Speaker 1: Ming You, M.D., Ph.D., Wisconsin Medical Center
Chemoprevention with aerosolized let-7 micro-RNA in mouse models of lung
cancer

9:30-10:00 AM

Speaker 2: Susan Mallery, D.D.S., Ph.D., Ohio State University
Location, location, location: oral cancer chemoprevention by local delivery

10:00-10:30 AM

Speaker 3: C.V. Rao, Ph.D., University of Oklahoma
Safer chemopreventive approaches to colonic adenoma prevention

10:30-10:45 AM

Break

10:45-11:15 AM

Speaker 4: D. Lynn Kirkpatrick, Ph.D., PHusis Therapeutics
Preventing Skin cancer in high risk individuals with Actinic Keratosis
using targeted AKT/PDK1 inhibitor, PHT-427

11:15-11:45 AM

Speaker 5: Roderick Dashwood, Ph.D., Texas A&M Health Science Center
Optimizing dosing regimens of Erlotinib and Sulindac in a preclinical model of
FAP

11:45-1:00 PM

Lunch

Day 2 Afternoon Session (1:00 to 4:00)
Session IV
Emerging Vaccines for Cancer Prevention
Co-Chairs: Steven Lipkin, M.D., Ph.D. and Shizuko Sei, M.D.
1:00-1:30 PM

Speaker 1: Steven Lipkin, M.D., Ph.D. Weill Cornell University
Immunoprevention for Lynch Syndrome

1:30-2:00 PM

Speaker 2: Mary (Nora) Disis, M.D., University of Washington
Vaccines targeting cancer initiation associated proteins

2:00-2:30 PM

Speaker 3: Richard Roden, Ph.D., Johns Hopkins University
Development of vaccines for broad protection against and elimination of HPV
infection

2:30-2:50 PM

Break

2:50-3:20 PM

Speaker 4: Robert Schoen, M.D., M.P.H., University of Pittsburgh
MUC1 vaccine for prevention of colorectal adenoma

3:20-3:50 PM

Speaker 5: Bryon Johnson, Ph.D., Wisconsin Medical Center
Development of a Kras preventive vaccine

4:00-6:00 PM

Poster Session

Day 3 Morning Session (8:00 to 12:00)
8:00-9:00 AM

Clinical Research Plenary Speaker
Powel Brown, M.D., Ph.D., MD Anderson Cancer Center
Novel cancer prevention strategies in the molecular era
Session V
Cancer Prevention Clinical Trials
Co-Chairs: Peter Allen and Eva Szabo

9:00-9:15 AM

Overview of the Cancer Prevention Clinical Trials Network (CP-CTNet)
Eva Szabo, M.D., Division of Cancer Prevention, NCI

Q&A to 9:30 AM

9:30-10:00 AM

Speaker 1: Peter Allen, M.D., Duke University
Intraductal Papillary Mucinous neoplasms of the pancreas: An opportunity to
prevent pancreatic cancer?

10:00-10:30 AM

Speaker 2, Eduardo Vilar-Sanchez, M.D., Ph.D., MD Anderson Cancer Center
Cancer immune-interception for Lynch Syndrome

10:30-10:50 AM

Break

10:50-11:20 AM

Speaker 3: Seema Khan, M.D., Northwestern University
Local transdermal drug delivery to the breast for cancer prevention

11:20-11:50 AM

Speaker 4: Andrew Chan, M.D., M.P.H., Massachusetts General Hospital
Novel strategies for aspirin prevention of cancer

12:00 PM

Adjourn